iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
IPO Year:
Exchange: NASDAQ
Website: icadmed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/18/2022 | Buy → Neutral | Guggenheim | |
| 1/5/2022 | $22.00 → $16.00 | Outperform | Oppenheimer |
| 11/10/2021 | $22.00 → $18.00 | Market Outperform | JMP Securities |
10-Q - ICAD INC (0000749660) (Filer)
8-K - ICAD INC (0000749660) (Filer)
10-Q/A - ICAD INC (0000749660) (Filer)
8-K - ICAD INC (0000749660) (Filer)
S-8 - ICAD INC (0000749660) (Filer)
8-K - ICAD INC (0000749660) (Filer)
10-Q - ICAD INC (0000749660) (Filer)
DEF 14A - ICAD INC (0000749660) (Filer)
10-K - ICAD INC (0000749660) (Filer)
8-K - ICAD INC (0000749660) (Filer)
Guggenheim downgraded icad from Buy to Neutral
Oppenheimer reiterated coverage of icad with a rating of Outperform and set a new price target of $16.00 from $22.00 previously
JMP Securities reiterated coverage of icad with a rating of Market Outperform and set a new price target of $18.00 from $22.00 previously
Guggenheim initiated coverage of iCAD with a rating of Buy and set a new price target of $24.00
BTIG initiated coverage of icad with a rating of Buy and set a new price target of $25.00
Oppenheimer initiated coverage of iCAD with a rating of Outperform and set a new price target of $27.00
B. Riley resumed coverage of iCAD with a rating of Buy and set a new price target of $23.00 from $18.00 previously
Oppenheimer initiated coverage of icad with a rating of Outperform and set a new price target of $27.00
Oppenheimer initiated coverage of iCAD with a rating of Outperform
Craig Hallum reiterated coverage of iCAD with a rating of Buy and set a new price target of $22.00 from $15.00 previously
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 87.0% to $0.4 during Monday's after-market session. The company's market cap stands at $6.2 million. MorphoSys (NASDAQ:MOR) stock increased by 25.94% to $23.35. The market value of their outstanding shares is at $3.5 billion. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 12.49% to $0.19. The market value of their outstanding shares is at $10.4 million. Mustang Bio (NASDAQ:MBIO) stock moved upwards by 11.91% to $0.23. The market value of their outstanding shares is at $2.9 million. icad (NASDAQ:ICAD) shares moved upwards by 10.75% to $1.75. The market value of their outstanding shares is at $46.4 million. Renalytix (NAS
icad (NASDAQ:ICAD) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 58.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $4.95 million which beat the analyst consensus estimate of $4.44 million by 11.58 percent. This is a 14.31 percent increase over sales of $4.33 million the same period last year.
icad (NASDAQ:ICAD) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:01 PM. Here's what investors need to know about the announcement. Earnings icad beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05. Revenue was down $1.75 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.03 which was followed by a 7.000000000000001% drop in the share price the next day. Here's a look at icad's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.08 -0.11 -0.11 -0.14 EPS Actual -0.05 -0.07 -0.14 -0.12 Revenue Estimate 6.27M 5.80M 6.21M 6.68M Revenue Actual 4.07M
icad (NASDAQ:ICAD) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $4.741 million which beat the analyst consensus estimate of $4.300 million by 10.26 percent. This is a 26.94 percent decrease over sales of $6.489 million the same period last year.
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. • MINISO Group Holding (NYSE:MNSO) is likely to report quarterly earnings at $0.27 per share on revenue of $530.30 million. • BioXcel Therapeutics (NASDAQ:BTAI) is likely to report quarterly loss at $0.91 per share on revenue of $710 thousand. • Enfusion (NYSE:ENFN) is likely to report quarterly earnings at $0.05 per share on revenue of $45.27 million. • Tupperware Brands (NYSE:TUP) is estimated to report earnings for its second quarter. • Kanzhun (NASDAQ:BZ) is expected to report quarterly earnings at $0.16 per share on revenue of $214.08 million. • Manchester United (
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G - ICAD INC (0000749660) (Subject)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G - ICAD INC (0000749660) (Subject)
SC 13G - ICAD INC (0000749660) (Subject)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G/A - ICAD INC (0000749660) (Subject)
NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024. Third Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.3 million, up 10% year over yearTotal revenues were $4.2 million, up 4% year over yearGross Profit Margin was 86%, consistent with prior year13 cloud deals closed during the quarter, key wins include: University California San Diego (UCSD) signed a 3-year Cloud deal Charlot
NASHUA, N.H., Nov. 05, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the third quarter ended September 30, 2024, after market close and host a conference call at 4:30 PM Eastern Time on Wednesday, November 13, 2024. Earnings call details are as follows: Toll Free: 877-545-0320International: 973-528-0002Participant Access Code: 509249Webcast: https://www.webcaster4.com/Webcast/Page/2879/51509 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutio
NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024. Second Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.2 million, up 7%Total revenues were $5.0 million, up 21%Gross Profit Margin was 84%, up from 81%GAAP Net loss from continuing operations ($1.7) million, improvement from ($2.3 million) "The second quarter of 2024 was highlighted by strong revenue growth of 21%, which demonstrat
NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday, August 13, 2024. Earnings call details are as follows: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 227167Webcast: https://www.webcaster4.com/Webcast/Page/2879/50989 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that ena
NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.0 million, up 10%Total revenues were $5.0 million, up 14%Gross Profit Margin % was 83%, up from 82%GAAP Net Loss from continuing operations ($1.2) million, improvement from ($3.1) millionOperating cash flow was ($1.2) million, improvement from ($1.5) million "Over the past year, we have demonstrated strong
NASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: https://www.webcaster4.com/Webcast/Page/2879/50453 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medica
NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 10:00 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: https://www.webcaster4.com/Webcast/Page/2879/50453 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medic
Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, today announced results for its fiscal fourth quarter and full year ended December 31, 2023, as compared to the corresponding period of the last fiscal year. Fourth Quarter 2023 Financial Highlights: Total ARR was $8.7 million, up 15%Total revenues were $4.7 million, up
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024. Earnings call details are as follows:Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 402294Webcast: https://www.webcaster4.com/Webcast/Page/2879/49733 About iCADiCAD, Inc. (NASDAQ:ICAD) is a global leader on a miss
NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2023. Highlights: Completed sale of Xoft, its therapy business line, to Elekta thereby enabling the Company to focus exclusively on its core business of AI-powered breast health solutions.Company re-introduces Annual Recurring Revenue (ARR) metrics to highlight progress of subscription sales and growing recurring revenue model.Company does not need to raise additional funding to pu
NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024. Third Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.3 million, up 10% year over yearTotal revenues were $4.2 million, up 4% year over yearGross Profit Margin was 86%, consistent with prior year13 cloud deals closed during the quarter, key wins include: University California San Diego (UCSD) signed a 3-year Cloud deal Charlot
NASHUA, N.H., Nov. 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader in clinically proven AI-powered cancer detection solutions, announced today that its ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) has received clearance from the U.S. Food and Drug Administration (FDA). This next-generation AI solution, trained using advanced deep learning convolutional neural networks (CNN), offers advancements in cancer detection and specificity, achieving a 6.3% improved area under the receiver operating characteristic curve (AUC) over prior version, significantly improving the identification of hard-to-find and aggressive cancers w
NASHUA, N.H., Nov. 05, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the third quarter ended September 30, 2024, after market close and host a conference call at 4:30 PM Eastern Time on Wednesday, November 13, 2024. Earnings call details are as follows: Toll Free: 877-545-0320International: 973-528-0002Participant Access Code: 509249Webcast: https://www.webcaster4.com/Webcast/Page/2879/51509 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutio
NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France. At JFR, iCAD will premier ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company's advanced AI solutions to healthcare providers worldwide. Global Commercial Availability of ProFound Cloud In its first two full quarters of U.S. availability, ProFound Cloud has processed nearly 100,000 cases, demonstrating rapid early a
NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will deliver a company presentation at 11:00 am ET on September 24, and host one-on-one meetings the following day, September 25. To learn more about the iAccess Alpha Buyside Best Ideas Fall Conference 2024, or to register and schedule a one-on-one meeting with iCAD, please vis
NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024. Second Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.2 million, up 7%Total revenues were $5.0 million, up 21%Gross Profit Margin was 84%, up from 81%GAAP Net loss from continuing operations ($1.7) million, improvement from ($2.3 million) "The second quarter of 2024 was highlighted by strong revenue growth of 21%, which demonstrat
NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday, August 13, 2024. Earnings call details are as follows: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 227167Webcast: https://www.webcaster4.com/Webcast/Page/2879/50989 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that ena
NASHUA, N.H. and WILLIAMSVILLE, N.Y. and RALEIGH, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with Windsong Radiology Group, one of US Radiology Specialists, Inc.'s national network of premier providers of diagnostic imaging services located in Western New York. This relationship aims to implement iCAD's ProFound AI Breast Health at Windsong Radiology center locations. The ProFound AI Breast Health Suite utilizes artificial intelligence to improve the accuracy and efficiency of mammography readings, thereby reducing false positives and unnecessary biopsies
NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine (SIIM) Annual Meeting. The company will also highlight its recently launched ProFound Cloud, an advanced software-as-a-service (SaaS) platform that offers medical providers a cost-effective, secure, and scalable solution for accessing and deploying the latest ProFound Breast Health Suite of AI solutions. Mark Trai
NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with investors at the event. Investors interested in scheduling time with iCAD are requested to register here: https://www.medinvestconferences.com/register To register to watch iCAD's investor presen
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
3 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately. Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field. For more than 20 years, she was Chair of the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) in New York City, a position from which she stepped down in January 2023. She continues to serve on the faculty of MSK; she holds the C
NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately. Mr. Doyle is a seasoned technology and healthcare executive with over 35 years of experience. He is currently the CEO of Spire Health, a leading healthcare technology company focused on improving health outcomes for cardiorespiratory patients through continuous virtual patient monitoring. Spire along with Mr. Doyle's recent companies all achieved measu
NASHUA, N.H., April 17, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Eric Lonnqvist as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula as Chief Product Officer (CPO) and Michelle Strong as Chief Operations Officer (COO), effective May 1. "As we explore new strategic approaches to execute our mission and expand our impact worldwide, experienced and visionary leadership is critical to the success of our organization. Eric, Vasu, and Michelle bring proven expertise to drive growth, increas
Stacey Stevens Resigns as President and CEO and as a Member of the Board Dana Brown Named President and CEO, remains Chairman of the Board NASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has accepted the resignation, for personal reasons, of Stacey Stevens as President and CEO. Stacey will remain with the Company through April 30, 2023 to ensure a smooth transition of the business. The Board has named Dana Brown as President and Chief Executive Officer, effective immediately. Ms. Brown will also retain her position as Chairman o
Daniel Shea appointed as interim Chief Financial Officer William Keyes hired as Senior Vice President, US Commercial Sales, AI NASHUA, N.H., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Daniel Shea, CPA, as interim Chief Financial Officer (CFO), effective immediately. The Company has launched a search for a full-time CFO, with the goal of completing that process in approximately 90 days. Also, after a rigorous search process, iCAD hired Bill Keyes as Senior Vice President, US Commercial Sales, AI. "We are pl
NASHUA, N.H., Jan. 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Dana Brown as Executive Chair of the Board of Directors. Ms. Brown has been a non-executive board member since February 2022. Prior to joining iCAD's board, Ms. Brown was the Senior Vice President, Chief Strategy and Operations Officer for Susan G. Komen®, the world's leading nonprofit breast cancer advocacy organization. "Looking ahead into 2023, key new strategic partnerships with leading organizations such as Google Health, Radiology Partners, the largest radiology practice in the cou
NASHUA, N.H., May 25, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Stephen P. Sarno as interim Chief Financial Officer (CFO), effective immediately. Mr. Sarno will assist with the transition as Charles Carter departs the Company this month. "Mr. Sarno brings a tremendous amount of experience to the Company, as he previously served in CFO roles at both private and public technology organizations including software companies offering SaaS-based models," said Stacey Stevens, President and CEO of iCAD, Inc. "On behalf of
NASHUA, N.H., Jan. 11, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today it has appointed Dana Brown and Timothy Norris Irish as new independent members of the Board of Directors, effective January 10, 2022. As previously announced, the Company also added Stacey Stevens, iCAD's President and incoming CEO to the Board of Directors, bringing the total number of Board members to eight. A 30-year technology industry veteran, Ms. Brown is currently the Senior Vice President, Chief Strategy and Operations Officer at Susan G. Komen®, the world's leading nonprofit breast cancer organiz
NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Board of Directors appointed Stacey Stevens as iCAD's President and Chief Executive Officer (CEO), effective March 1, 2022. Stevens, who has served as the Company's President since 2019, will also join the Company's Board of Directors. Michael Klein, who currently serves as the Company Chairman and CEO, will continue to serve as Chairman of iCAD's Board of Directors. "On behalf of the entire Board of Directors, I would like to congratulate Ms. Stevens on this appointment. It has been a privilege t
International Multi-Center Study to Commence January 2021 University of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating First European Patient Treated for Brain Metastasis with Xoft IORT System NASHUA, N.H., Dec. 29, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Santosh Kesari, MD, PhD, a world-renowned neuro-oncologist, as Principal Investigator of its International multi-center clinical trial evaluating the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® as the sole radiation therapy to treat recurrent glioblastoma (